Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $1.7 million.

  • Iradimed's Tax Provisions rose 2573.32% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 31.01%. This contributed to the annual value of $5.7 million for FY2024, which is 382.64% down from last year.
  • According to the latest figures from Q3 2025, Iradimed's Tax Provisions is $1.7 million, which was up 2573.32% from $1.6 million recorded in Q2 2025.
  • Iradimed's 5-year Tax Provisions high stood at $2.6 million for Q4 2023, and its period low was -$779172.0 during Q4 2021.
  • For the 5-year period, Iradimed's Tax Provisions averaged around $1.1 million, with its median value being $1.1 million (2024).
  • Data for Iradimed's Tax Provisions shows a peak YoY increase of 28456.35% (in 2021) and a maximum YoY decrease of 11522.96% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Iradimed's Tax Provisions stood at -$779172.0 in 2021, then soared by 232.19% to $1.0 million in 2022, then soared by 148.93% to $2.6 million in 2023, then fell by 26.08% to $1.9 million in 2024, then dropped by 9.19% to $1.7 million in 2025.
  • Its Tax Provisions stands at $1.7 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.3 million for Q1 2025.